Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesPDS Biotechnology Corp

PDS Biotechnology Corp

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.23 USD 0.06 ( 5.13%)
Last update at 2026-11-06T21:01:00Z
VOLUME
2865116
Market Cap
114.07M

Momentum Score

…

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.17
Low
1.27
High
52 Week Price Range
2.59
Low
10.27
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.17
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.91
ROE
-112.25%
Net Debt
-32.71M
ROCE
-91.07%
Diluted EPS TTM
-1.38

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -42.05M -21.43M -14.85M -7.38M -43.65M
Net income -40.85M -16.92M -14.85M -7.00M -40.87M
Selling general administrative 12.24M 10.18M 6.96M 10.98M 14.29M
Reconciled depreciation 0.00M 0.01M 0.02M 0.10M 0.17M
Ebit -41.67M -21.44M -14.90M -21.03M -29.49M
Ebitda -40.74M -21.43M -14.83M -16.73M -29.31M
Depreciation and amortization 0.94M 0.01M 0.07M 4.31M 0.17M
Non operating income net other - - 0.06M - -
Operating income -41.67M -21.44M -14.90M -21.03M -43.10M
Other operating expenses 41.67M 21.44M 14.90M 17.08M 30.36M
Interest expense 1.32M 0.00M 0.00M 0.03M 1.43M
Tax provision -1.20M -4.52M 0.00M -0.38M -2.78M
Interest income 0.94M 0.00M 0.06M 0.35M 0.87M
Net interest income -0.38M 0.00M 0.06M 0.32M -0.55M
Income tax expense -1.20M -4.52M -0.06M -0.38M -2.78M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 41.67M 21.44M 14.90M 17.08M 30.36M
Total other income expense net -0.38M 0.00M 0.06M 13.65M -12.74M
Net income from continuing ops -40.85M -16.92M -14.85M -7.00M -40.87M
Net income applicable to common shares -40.85M -16.92M -14.85M -7.00M -3.84M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 59.39M 77.01M 67.20M 30.89M 14.49M
Other current assets 2.49M 2.66M 1.60M 1.50M 2.31M
Total liab 33.26M 33.01M 3.99M 3.76M 2.79M
Total stockholder equity 26.13M 44.00M 63.21M 27.13M 11.70M
Other current liab 2.42M 8.31M 2.19M 1.74M 1.60M
Common stock 0.01M 0.01M 0.01M 0.01M 0.00M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.00M
Retained earnings -144.50M -101.56M -60.70M -43.79M -28.94M
Other assets 0.00M - - 0.55M -
Cash 56.56M 73.82M 65.24M 28.84M 12.16M
Total current liabilities 13.63M 9.82M 3.76M 3.27M 2.79M
Net debt -32.71M -50.35M -64.75M -28.23M -12.16M
Short term debt 4.22M 0.29M 0.26M 0.12M -
Short long term debt 4.17M - - - -
Short long term debt total 23.85M 23.47M 0.49M 0.61M -
Other stockholder equity 170.62M 145.55M 123.90M 70.91M 40.63M
Property plant equipment - 0.53M 0.36M 0.55M 0.02M
Total current assets 59.06M 76.48M 66.84M 30.34M 14.47M
Net tangible assets - 44.00M 63.21M 27.13M 11.70M
Long term debt 19.51M 23.02M - - -
Accounts payable 6.98M 1.22M 1.31M 1.42M 1.20M
Accumulated other comprehensive income - - - - -0.09M
Common stock total equity - 0.01M - 0.01M 0.00M
Retained earnings total equity - -101.56M - -43.79M -
Non currrent assets other -0.00M 0.37M - 0.55M 0.02M
Non current assets total 0.34M 0.53M 0.36M 0.55M 0.02M
Capital lease obligations 0.18M 0.45M 0.49M 0.61M -
Long term debt total - 23.02M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments - - 0.00M 29.38M 0.00M
Change to liabilities 6.04M -0.11M 0.22M -1.98M 0.79M
Total cashflows from investing activities - - - 29.38M 29.38M
Net borrowings 24.55M 25.00M 25.00M 25.00M -0.02M
Total cash from financing activities 34.29M 48.89M 29.83M 0.75M -20.27M
Change to operating activities 4.57M 0.18M 0.85M -2.63M 0.36M
Net income -40.85M -16.92M -14.85M -7.00M -40.87M
Change in cash 8.58M 36.40M 16.68M 12.06M -53.42M
Begin period cash flow 65.24M 28.84M 12.16M 0.10M 88.07M
End period cash flow 73.82M 65.24M 28.84M 12.16M 34.65M
Total cash from operating activities -25.71M -12.49M -13.15M -18.07M -33.15M
Issuance of capital stock 9.86M 48.54M 29.76M 0.75M 0.00M
Depreciation 0.00M 0.01M 0.02M 0.10M 0.17M
Other cashflows from investing activities - - - 29.38M -
Sale purchase of stock 10.01M - 29.83M 0.75M 0.72M
Other cashflows from financing activities 24.88M 0.34M 0.07M 29.38M 0.72M
Change to netincome 5.20M 4.35M 0.61M -6.57M 1.05M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Cash flows other operating 3.73M - 0.87M - -
Cash and cash equivalents changes 8.58M - 16.68M - -
Change in working capital 4.47M 0.08M 1.07M -4.60M -3.43M
Stock based compensation 5.20M 4.11M 0.45M 3.18M 7.61M
Other non cash items 5.47M 0.24M 0.16M -9.36M 0.53M
Free cash flow -25.71M -12.49M -13.15M -18.07M -33.15M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
PDSB
PDS Biotechnology Corp		 0.06
5.13%		 1.23 - - - 4.47 -2.10
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

PDS Biotechnology Corp

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

303A College Road East, Princeton, NJ, United States, 08540

800 208 3343

https://www.pdsbiotech.com

25

Name Title Year Born
Dr. Frank K. Bedu-Addo Ph.D. Pres, CEO & Director 1965
Mr. Matthew C. Hill CPA CFO, Principal Financial & Accounting Officer 1969
Dr. Gregory L. Conn Ph.D. Chief Scientific Officer 1955
Ms. Lauren V. Wood M.D. Chief Medical Officer 1960
Dr. Joe J. Dervan VP of R&D NA
Ms. Deanne Randolph VP of Commercial Devel. & Head of Investor Relations NA
Mr. Spencer Brown J.D. Sr. VP & Gen. Counsel NA
Ms. Nathalie Riebel Sr. VP of Clinical Operations NA
Mr. Sanjay Zaveri Sr. VP of Bus. Devel. NA
Ms. Janetta Trochimiuk Controller 1963

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…